Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Medsafe consents cystic fibrosis drug Trikafta for use in New Zealandon December 8, 2021 at 4:32 pm
Medsafe has given consent for the use of Trikafta to treat cystic fibrosis in patients in New Zealand. Pharmaceuticals company Vertex on Thursday announced the consent, saying 350 Kiwis will now be ...
- A faster “code breaker” to analyze human DNAon December 8, 2021 at 12:08 pm
Researchers at the University of Missouri are working to help scientists speed up their data analysis of human genomes along the way to making new scientific discoveries. By speeding up the data ...
- Lower airways distinct in cystic fibrosis, even in younger childrenon December 8, 2021 at 7:06 am
There are distinct differences in airway microbiota and inflammation in lower airway samples of patients with cystic fibrosis across a range of ages, researchers reported in PLOS ONE.“We compared ...
- Randy Sims Fights the Good Fight with Golfon December 7, 2021 at 1:48 pm
Sims Executive Search CEO admits that some days are a struggle after being diagnosed with Cystic Fibrosis at age 10, but golf has helped him through life's valleys.
- Specific Biologics Inc. Announces Therapeutic Development Award from the Cystic Fibrosis Foundationon December 7, 2021 at 6:00 am
Specific Biologics Inc. ("Specific"), an early-stage biotechnology company developing novel gene editing technologies, today announced that it will receive more than US$527,000 to support the ...
- CF Foundation Awards More Than $1.8M to Three Companies for Genetic Therapies Researchon December 7, 2021 at 6:00 am
The Cystic Fibrosis Foundation announced today that it has awarded more than $1.8 million to three companies for early-stage research into potential genetic therapies for cystic fibrosis as part of ...
- CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipientson December 6, 2021 at 5:03 am
Today, the Cystic Fibrosis Foundation announced its investment of $3.5 million in Pulmocide Limited, a U.K.-based biotech company, to develop an inhaled drug (opelconazole) to prevent Aspergillus ...
- Pulmocide Receives Investment from the Cystic Fibrosis Foundationon December 6, 2021 at 5:03 am
The Cystic Fibrosis Foundation invested $3.5 million in Pulmocide as part of the CF Foundation’s Lung Transplant Initiative; Funding supports prophylaxis study in lung transplan ...
- MSU lab studies promising new drug to treat cystic fibrosison December 3, 2021 at 12:01 pm
A research lab at Michigan State University is studying the effects of the groundbreaking drug Trikafta on the microbiomes of people with cystic fibrosis.
- Stittsville woman with cystic fibrosis receives game-changing drug after initial denialon November 25, 2021 at 4:06 pm
Unpleasant though the experience was, it told the 23-year-old Stittsville student and cystic fibrosis patient that the life-saving medication she’d started taking that day was working, expelling a ...
via Bing News